Prognostic factors for patients with heparin-induced thrombocytopenia: a systematic review

被引:3
作者
Colarossi, Giorgia [1 ]
Schnoering, Heike [1 ]
Trivellas, Andromahi [2 ]
Betsch, Marcel [3 ]
Hatam, Nima [1 ]
Eschweiler, Joerg [4 ]
Tingart, Markus [4 ]
Migliorini, Filippo [4 ]
机构
[1] RWTH Aachen Univ Clin, Dept Cardiac & Thorac Surg, Pauwelstr 31, D-52074 Aachen, Germany
[2] Univ Calif Los Angeles, David Geffen Sch Med, Dept Orthopaed, Los Angeles, CA 90095 USA
[3] UTOSM, Womens Coll Hosp, Toronto, ON, Canada
[4] RWTH Aachen Univ Clin, Dept Orthopaed Surg, Pauwelstr 31, D-52074 Aachen, Germany
关键词
Heparin-induced thrombocytopenia; HIT; Prognostic factors; Systematic review; DIRECT THROMBIN INHIBITORS; ARGATROBAN ANTICOAGULATION; RECOMBINANT HIRUDIN; RISK-FACTORS; LEPIRUDIN; MANAGEMENT; THERAPY; BIVALIRUDIN; PROPHYLAXIS; PREVENTION;
D O I
10.1007/s11096-020-01166-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Little is known with regards to the prognostic factors for patients with suspected or diagnosed Heparin-Induced Thromobocytopenia (HIT). The role of patient and therapy characteristics may play a role in predicting the outcome.Aim of the reviewTo investigate the role of patient and therapy characteristics as potential prognostic factors for HIT-related complications (haemorrhagic and thromboembolic events), and mortality.MethodThe present systematic review was conducted according to the PRISMA statement. In September 2020, the main online databases were accessed: Pubmed, EMBASE, Scopus, Google Scholar. All the clinical trials concerning the management of patients with suspected or confirmed HIT were eligible. Studies evaluating the use of oral anticoagulants (e.g. vitamin K antagonists, Apixaban) were not considered, along with those comparing the use of heparin. For pairwise correlation, the Pearson Product-Moment Correlation Coefficient (r) was used. The final effect was evaluated according to the Cauchy-Schwarz inequality.ResultsData from 33 clinical studies (4338 patients) were retrieved. The overall mean age was 62.3 +/- 6.6 years old. Patients with HIT-related thromboembolism at the moment of diagnosis were associated with greater rate of haemorrhages (P > 0.0001), thromboembolism (P > 0.0001) and mortality (P = 0.001). Patients with more comorbidities at diagnosis were associated with a greater risk of haemorrhages (P = 0.07), thromboembolism (P = 0.002) and mortality (P = 0.002). Patients with longer duration of the therapy were associated with lower rate of mortality (P = 0.04).ConclusionsPatient comorbidities, presence of HIT-related thromboembolism on admission and shorter anticoagulant therapy were found to be negative prognostic factors. Thrombocythemia on admission, patients age and gender did not influence the overall outcome.
引用
收藏
页码:449 / 460
页数:12
相关论文
共 57 条
  • [11] Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysis
    Cuker, Adam
    Gimotty, Phyllis A.
    Crowther, Mark A.
    Warkentin, Theodore E.
    [J]. BLOOD, 2012, 120 (20) : 4160 - 4167
  • [12] A comparison of direct thrombin inhibitors in the treatment of heparin-induced thrombocytopenia: a single institution experience
    Curzio, Karen M.
    Cheng-Lai, A.
    Kheyfets, V.
    Sinnet, M.
    Billett, H. H.
    [J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2009, 28 (02) : 117 - 123
  • [13] Heparin-induced thrombocytopenia (an overview)
    Daneschvar, H. L.
    Daw, H.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2007, 61 (01) : 130 - 137
  • [14] Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia
    Dang, CH
    Durkalski, VL
    Nappi, JM
    [J]. PHARMACOTHERAPY, 2006, 26 (04): : 461 - 468
  • [15] Bleeding risk factors associated with argatroban therapy in the critically ill
    Doepker, Bruce
    Mount, Kari L.
    Ryder, Lindsay J.
    Gerlach, Anthony T.
    Murphy, Claire V.
    Philips, Gary S.
    [J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2012, 34 (04) : 491 - 498
  • [16] Donovan Jennifer L, 2010, J Pharm Pract, V23, P226, DOI 10.1177/0897190010362171
  • [17] Argatroban Versus Bivalirudin in the Treatment of Suspected or Confirmed Heparin-Induced Thrombocytopenia
    Duewell, Brittney E.
    Briski, Matthew J.
    Feih, Joel T.
    Rinka, Joseph R. G.
    Tawil, Justin N.
    [J]. JOURNAL OF PHARMACY PRACTICE, 2021, 34 (04) : 529 - 534
  • [18] Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four/heparin antibodies
    Dyke, Cornelius M.
    Aldea, Gabriel
    Koster, Andreas
    Smedira, Nicholas
    Avery, Edwin
    Aronson, Solomon
    Spiess, Bruce D.
    Lincoff, A. Michael
    [J]. ANNALS OF THORACIC SURGERY, 2007, 84 (03) : 836 - 840
  • [19] A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia
    Farner, B
    Eichler, P
    Kroll, H
    Greinacher, A
    [J]. THROMBOSIS AND HAEMOSTASIS, 2001, 85 (06) : 950 - 957
  • [20] Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis
    Fischer, KG
    van de Loo, A
    Böhler, J
    [J]. KIDNEY INTERNATIONAL, 1999, 56 : S46 - S50